地西他滨治疗骨髓增生异常综合征的疗效分析

Effects of decitabine in treatment of patients with myelodysplastic syndrome

目的探讨地西他滨治疗骨髓增生异常综合征(MDS)的疗效及危险因素。方法收集65例MDS患者的临床资料,均接受地西他滨治疗,分析年龄、病程、国际预后积分系统(IPSS)分组、血小板计数等与疗效的关系,分析影响地西他滨治疗MDS效果的危险因素。结果所有患者治疗总有效率为78.46%。年龄、病程、IPSS分组、血小板计数与地西他滨治疗MDS的疗效有相关性,差异有统计学意义(P<0.05)。Logistic回归分析显示,年龄大、病程长、IPSS分组高、血小板计数低是影响地西他滨治疗MDS效果的危险因素(OR>1,P<0.05)。结论地西他滨治疗MDS效果显著,其效果与年龄、病程、IPSS分组、血小板计数有关。

Objective To investigate the efficacy and risk factors of decitabine in the treatment of patients with myelodysplastic syndrome (MDS). Methods The clinical materials of 65 MDS patients with decitabine were collected. Relationships between efficacy and age,course of disease,grouping of International Prognostic Score System (IPSS),platelet count were analyzed. The risk factors affecting efficacy of decitabine in the treatment of MDS were analyzed. Results The total effective rate was 78. 46% in all the patients. Age,course of disease,grouping of IPSS and platelet count were significantly correlated with the efficacy of decitabine in the treatment of MDS (P < 0. 05).Logistic regression analysis showed that older age,long course of disease,high grouping of IPSS and low platelet count were the risk factors affecting the efficacy of decitabine in the treatment of MDS (OR >1,P <0. 05). Conclusion The decitabine is effective in the treatment of MDS,and its efficacy is related with age,course of disease,grouping of IPSS and platelet count.